Beliefs about medicines’ association with endocrine therapy adherence in early breast cancer survivors in Croatia

1 H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal and F. Bray, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin. 71(3) (2021) 209–249; https://doi.org/10.3322/caac.21660 Search in Google Scholar

2 European Cancer Information System, Estimates of cancer incidence and mortality in 2020; https://ecis.jrc.ec.europa.eu/; last access date May 15, 2023. Search in Google Scholar

3 V. Foulon, P. Schöffski and P. Wolter, Patient adherence to oral anticancer drugs: An emerging issue in modern oncology, Acta Clin. Belg. 66(2) (2011) 85–96; https://doi.org/10.2143/ACB.66.2.2062525 Search in Google Scholar

4 F. Cardoso, S. Kyriakides, S. Ohno, F. Penault-Llorca, P. Poortmans, I. T. Rubio, S. Zackrisson and E. Senkus, Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann. Oncol. 30(10) (2019) 1194–1220; https://doi.org/10.1093/annonc/mdz173 Search in Google Scholar

5 B. Makubate, P. T. Donnan, J. A. Dewar, A. M. Thompson and C. McCowan, Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality, Br. J. Cancer 108(7) (2013) 1515–1524; https://doi.org/10.1038/bjc.2013.116 Search in Google Scholar

6 L. Li, B. Chang, X. Jiang, X. Fan, Y. Li, T. Li, S. Wu, J. Zhang, S. Kariminia and Q. Li, Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer, BMC Cancer 18(1) (2018) Article ID 977 (11 pages); https://doi.org/10.1186/s12885-018-4878-4 Search in Google Scholar

7 D. L. Hershman, T. Shao, L. H. Kushi, D. Buono, W. Y. Tsai, L. Fehrenbacher, M. Kwan, S. L. Gomez and A. I. Neugut, Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer, Breast Cancer Res. Treat. 126(2) (2011) 529–537; https://doi.org/10.1007/s10549-010-1132-4 Search in Google Scholar

8 T. L. Lash, M. P. Fox, J. L. Westrup, A. K. Fink and R. A. Silliman, Adherence to tamoxifen over the five-year course, Breast Cancer Res. Treat. 99(2) (2006) 215–220; https://doi.org/10.1007/s10549-006-9193-0 Search in Google Scholar

9 J. Y. Lee and Y. H. Min, Relationships between determinants of adjuvant endocrine therapy adherence in breast cancer, BMC Womens Health 18(1) (2018) 1–8; https://doi.org/10.1186/s12905-018-0522-3 Search in Google Scholar

10 B. Pistilli, A. Paci, A. R. Ferreira, A. Di Meglio, V. Poinsignon, A. Bardet, G. Menvielle, A. Dumas, S. Pinto, S. Dauchy, L. Fasse, P. H. Cottu, F. Lerebours, C. Coutant, A. Lesur, O. Tredan, P. Soulie, L. Vanlemmens, C. Jouannaud, C. Levy, S. Everhard, P. Arveux, A. L. Martin, A. Dima, N. U. Lin, A. H. Partridge, S. Delaloge, S. Michiels, F. André and I. Vaz-Luis, Serum detection of nonadherence to adjuvant tamoxifen and breast cancer recurrence risk, J. Clin. Oncol. 38(24) (2020) 2762–2772; https://doi.org/10.1200/JCO.19.01758 Search in Google Scholar

11 E. M. Quinn, C. Fleming and M. J. O’Sullivan, Endocrine therapy adherence : a cross-sectional study of factors affecting adherence and discontinuation of therapy, Ir. J. Med. Sci. 185(2) (2016) 383–392; https://doi.org/10.1007/s11845-015-1307-4 Search in Google Scholar

12 V. Ziller, M. Kalder, U. S. Albert, W. Holzhauer, M. Ziller, U. Wagner and P. Hadji, Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer, Ann. Oncol. 20(3) (2009) 431–436; https://doi.org/10.1093/annonc/mdn646 Search in Google Scholar

13 L. R. Ayres, O. Baldoni Ade, A. P. Borges and L. R. Pereira, Adherence and discontinuation of oral hormonal therapy in patients with hormone receptor positive breast cancer, Int. J. Clin. Pharm. 36(1) (2014) 45–54; https://doi.org/10.1007/s11096-013-9833-5 Search in Google Scholar

14 R. Font, J. A. Espinas, A. Barnadas, A. Izquierdo, J. Galceran, F. Saladie, R. Marcos-Gragera, A. Torrent, P. Manchon-Walsh and J. M. Borras, Influence of adherence to adjuvant endocrine therapy on disease-free and overall survival: a population-based study in Catalonia, Spain, Breast Cancer Res. Treat. 175(3) (2019) 733–740; https://doi.org/10.1007/s10549-019-05201-3 Search in Google Scholar

15 D. L. Hershman, L. H. Kushi, T. Shao, D. Buono, A. Kershenbaum, W. Y. Tsai, L. Fehrenbacher, S. Lin Gomez, S. Miles and A. I. Neugut, Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients, J. Clin. Oncol. 28(27) (2010) 4120–4128; https://doi.org/10.1200/JCO.2009.25.9655 Search in Google Scholar

16 S. McGuinness, L. Hughes, R. Moss-Morris, M. Hunter, S. Norton and Z. Moon, Adherence to adjuvant endocrine therapy among White British and ethnic minority breast cancer survivors in the United Kingdom, Eur. J. Cancer Care 31(6) (2022) Article ID 13722 (11 pages); https://doi.org/10.1111/ecc.13722 Search in Google Scholar

17 Z. Moon, R. Moss-Morris, M. S. Hunter, S. Carlisle and L. D. Hughes, Barriers and facilitators of adjuvant hormone therapy adherence and persistence in women with breast cancer: A systematic review, Patient Prefer. Adher. 11 (2017) 305–322; https://doi.org/10.2147/PPA.S126651 Search in Google Scholar

18 C. C. Murphy, L. K. Bartholomew, M. Y. Carpentier, S. M. Bluethmann and S. W. Vernon, Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: A systematic review, Breast Cancer Res. Treat. 134(2) (2012) 459–478; https://doi.org/10.1007/s10549-012-2114-5 Search in Google Scholar

19 I. Yussof, N. A. Mohd Tahir, E. Hatah and N. Mohamed Shah, Factors influencing five-year adherence to adjuvant endocrine therapy in breast cancer patients: A systematic review, Breast 62 (2022) 22–35; https://doi.org/10.1016/j.breast.2022.01.012 Search in Google Scholar

20 M. P. van Herk-Sukel, L. V. Van De Poll-Franse, A. C. Voogd, G. A. P. Nieuwenhuijzen, J. W. W. Coebergh and R. M. C. Herings, Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: A population-based analysis, Breast Cancer Res. Treat. 122(3) (2010) 843–851; https://doi.org/10.1007/s10549-009-0724-3 Search in Google Scholar

21 D. M. Waterhouse, K. A. Calzone, C. Mele and D. E. Brenner, Adherence to oral tamoxifen: A comparison of patient self-report, pill counts, and microelectronic monitoring, J. Clin. Oncol. 11(6) (1993) 1189–1197; https://doi.org/10.1200/JCO.1993.11.6.1189 Search in Google Scholar

22 C. Lin, R. Clark, P. Tu, H. B. Bosworth and L. L. Zullig, Breast cancer oral anti-cancer medication adherence: a systematic review of psychosocial motivators and barriers, Breast Cancer Res. Treat. 165(2) (2017) 247–260; https://doi.org/10.1007/s10549-017-4317-2 Search in Google Scholar

23 M. A. Franzoi, E. Agostinetto, M. Perachino, L. del Mastro, E. de Azambuja, I. Vaz-Luis, A. H. Partridge and M. Lambertini, Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer, Lancet Oncol. 22(7) (2021) e303-e313; https://doi.org/10.1016/S1470-2045(20)30666-5 Search in Google Scholar

24 L. K. Lambert, L. G. Balneaves, A. F. Howard and C. C. Gotay, Patient – reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review, Breast Cancer Res. Treat. 167(3) (2017) 615–633; https://doi.org//10.1007/s10549-017-4561-5 Search in Google Scholar

25 S. Sawesi, J. S. Carpenter and J. Jones, Reasons for nonadherence to tamoxifen and aromatase inhibitors for the treatment of breast cancer: A literature review, Clin. J. Oncol. Nurs. 18(3) (2014) 50–57; https://doi.org/10.1188/14.CJON.E50-E57 Search in Google Scholar

26 K. L. Smith, N. Verma, A. L. Blackford, J. Lehman, K. Westbrook, D. Lim, J. Fetting, A. C. Wolff, D. Jelovac, R. S. Miller, R. Connolly, D. K. Armstrong, R. Nunes, K. Visvanathan, C. Riley, K. Papathakis, N. Zafman, J. Y. Sheng, C. Snyder and V. Stearns, Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation, NPJ Breast Cancer 8(1) (2022) Article ID 53 (13 pages); https://doi.org/10.1038/s41523-022-00414-0 Search in Google Scholar

27 W. Wulaningsih, H. Garmo, J. Ahlgren, L. Holmberg, Y. Folkvaljon, A. Wigertz, M. Van Hemelrijck and M. Lambe, Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity, Breast Cancer Res. Treat. 172(1) (2018) 167–177; https://doi.org/10.1007/s10549-018-4890-z Search in Google Scholar

28 J. Brett, N. J. Hulbert-Williams, D. Fenlon, M. Boulton, F. M. Walter, P. Donnelly, B. Lavery, A. Morgan, C. Morris, R. Horne and E. Watson, Psychometric properties of the Beliefs about Medicine Questionnaire-adjuvant endocrine therapy (BMQ-AET) for women taking AETs following early-stage breast cancer, Health Psychol. Open 4(2) (2017); https://doi.org/10.1177/2055102917740469 Search in Google Scholar

29 J. Brett, D. Fenlon, M. Boulton, N. J. Hulbert-Williams, F. M. Walter, P. Donnelly, B. Lavery, A. Morgan, C. Morris and E. Watson, Factors associated with intentional and unintentional non-adherence to adjuvant endocrine therapy following breast cancer, Eur. J. Cancer Care 27(1) (2018) 1–9; https://doi.org/10.1111/ecc.12601 Search in Google Scholar

30 H. Foot, A. La Caze, G. Gujral and N. Cottrell, The necessity-concerns framework predicts adherence to medication in multiple illness conditions: A meta-analysis, Patient Educ. Couns. 99(5) (2016) 706–717; https://doi.org/10.1016/j.pec.2015.11.004 Search in Google Scholar

31 R. Horne, J. Weinman and M. Hankins, The beliefs about medicines questionnaire: The development and evaluation of a new method for assessing the cognitive representation of medication, Psychol. Health 14 (1999) 1–24; https://doi.org/10.1080/08870449908407311 Search in Google Scholar

32 R. Horne, S. C. E. Chapman, R. Parham, N. Freemantle, A. Forbes and V. Cooper, Understanding patients’ adherence-related beliefs about medicines prescribed for long-term conditions: A meta-analytic review of the Necessity-Concerns Framework, PLoS One 8(12) e80633 (24 pages); https://doi.org/10.1371/journal.pone.0080633 Search in Google Scholar

33 R. Horne and J. Weinman, Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness, J. Psychosom. Res. 47(6) (1999) 555–567; https://doi.org/10.1016/s0022-3999(99)00057-4 Search in Google Scholar

34 C. T. Toivonen, T. M. Williamson, L. E. Carlson and L. M. Walker, Potentially modifiable factors associated with adherence to adjuvant endocrine therapy among breast cancer survivors: A systematic review, Cancers (Basel) 13(1) (2020) Article ID 107 (22 pages); https://doi.org/10.3390/cancers13010107 Search in Google Scholar

35 A. H. Y. Chan, R. Horne, M. Hankins and C. Chisari, The medication adherence report scale: A measurement tool for eliciting patients’ reports of nonadherence, Br. J. Clin. Pharmacol. 86(7) (2020) 1281–1288; https://doi.org/10.1111/bcp.14193 Search in Google Scholar

36 S. T. de Vries, J. C. Keers, R. Visser, D. de Zeeuw, F. M. Haaijer-Ruskamp, J. Voorham and P. Denig, Medication beliefs, treatment complexity, and non-adherence to different drug classes in patients with type 2 diabetes, J. Psychosom. Res. 76(2) (2014) 134–138; https://doi.org/10.1016/j.jpsy-chores.2013.11.003 Search in Google Scholar

37 Z. Moon, R. Moss-Morris, M. S. Hunter and L. D. Hughes, More than just side-effects: The role of clinical and psychosocial factors in non-adherence to tamoxifen, Br. J. Health Psychol. 22(4) (2017) 998–1018; https://doi.org/10.1111/bjhp.12274 Search in Google Scholar

38 J. Charan and T. Biswas, How to calculate sample size for different study designs in medical research?, Indian J. Psychol. Med. 35(2) (2013) 121–126; https://doi.org/10.4103/0253-7176.116232 Search in Google Scholar

39 E. A. Grunfeld, M. S. Hunter, P. Sikka and S. Mittal, Adherence beliefs among breast cancer patients taking tamoxifen, Patient Educ. Couns 59(1) (2005) 97–102; https://doi.org/10.1016/j.pec.2004.10.005 Search in Google Scholar

40 Y. Sheng and Z. Sheng, Is coefficient alpha robust to non-normal data?, Front Psychol. 3 (2012) Article ID 34 (13 pages); https://doi.org/10.3389/fpsyg.2012.00034 Search in Google Scholar

41 T. M. Salgado, E. J. Davis, K. B. Farris, S. Fawaz, P. Batra and N. L. Henry, Identifying socio-demographic and clinical characteristics associated with medication beliefs about aromatase inhibitors among postmenopausal women with breast cancer, Breast Cancer Res. Treat. 163(2) (2017) 311–319; https://doi.org/10.1007/s10549-017-4177-9 Search in Google Scholar

42 A. L. Sutton, T. M. Salgado, J. He, A. Hurtado-de-Mendoza and V. B. Sheppard, Sociodemographic, clinical, psychosocial, and healthcare-related factors associated with beliefs about adjuvant endocrine therapy among breast cancer survivors, Support. Care in Cancer 28(9) (2020) 4147–4154; https://doi.org/10.1007/s00520-019-05247-5 Search in Google Scholar

43 K. C. Kadakia, K. M. Kidwell, D. L. Barton, A. F. Schott, D. F. Hayes, J. J. Griggs and N. L. Henry, Factors influencing the use of extended adjuvant endocrine therapy, Breast Cancer Res. Treat. 175(1) (2019) 181–189; https://doi.org/10.1007/s10549-019-05145-8 Search in Google Scholar

44 E. E. Bright, K. J. Petrie, A. H. Partridge and A. L. Stanton, Barriers to and facilitative processes of endocrine therapy adherence among women with breast cancer, Breast Cancer Res. Treat. 158(2) (2016) 243–251; https://doi.org/10.1007/s10549-016-3871-3 Search in Google Scholar

45 A. L. Stanton, K. J. Petrie and A. H. Partridge, Contributors to nonadherence and nonpersistence with endocrine therapy in breast cancer survivors recruited from an online research registry, Breast Cancer Res. Treat. 145(2) (2014) 525–534; https://doi.org/10.1007/s10549-014-2961-3 Search in Google Scholar

46 R. J. Thorneloe, L. H. Hall, F. M. Walter, L. Side, K. E. Lloyd and S. G. Smith, Knowledge of potential harms and benefits of tamoxifen among women considering breast cancer preventive therapy, Cancer Prev. Res. 13(4) (2020) 411–421; https://doi.org/10.1158/1940-6207.CAPR-19-0424 Search in Google Scholar

47 Y. Kim, Y. H. Min and S. B. Lee, Beliefs and attitudes toward endocrine therapy in patients with hormone receptor-positive breast cancer, Health Care Women Int. 42(7-9) (2021) 1086–1097; https://doi.org/10.1080/07399332.2020.1802460 Search in Google Scholar

48 L. B. Wenzel, D. L. Fairclough, M. J. Brady, D. Cella, K. M. Garrett, B. C. Kluhsman, L. A. Crane and A. C. Marcus, Age-related differences in the quality of life of breast carcinoma patients after treatment, Cancer 86(9) (1999) 1768–1774; https://doi.org/10.1002/(SICI)1097-0142(19991101)86:9<1768 Search in Google Scholar

49 R. Condorelli and I. Vaz-Luis, Managing side effects in adjuvant endocrine therapy for breast cancer, Expert Rev. Anticancer Ther. 18(11) (2018) 1101–1112; https://doi.org/10.1080/14737140.2018.1520096 Search in Google Scholar

50 T. Sella, P. D. Poorvu, K. J. Ruddy, S. I. Gelber, R. M. Tamimi, J. M. Peppercorn, L. Schapira, V. F. Borges, S. E. Come, A. H. Partridge and S. M. Rosenberg, Impact of fertility concerns on endocrine therapy decisions in young breast cancer survivors, Cancer 127(16) (2021) 2888–2894; https://doi.org/10.1002/cncr.33596 Search in Google Scholar

51 C. Castillo and N. Camejo, Impact of breast cancer treatments on fertility and the importance of timing for a fertility preservation intervention, Revista de Senologia y Patologia Mamaria 34(4) (2022) 305–311; https://doi.org/10.1016/j.senol.2021.08.004 Search in Google Scholar

52 J. Howard-Anderson, P. A. Ganz, J. E. Bower and A. L. Stanton, Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: A systematic review, J. Natl. Cancer Inst. 104(5) (2012) 386–405; https://doi.org/10.1093/jnci/djr541 Search in Google Scholar

53 A. Philipovskiy, A. Campbell, R. Heydarian, B. Castillo, A. K. Dwivedi, R. McCallum, R. Aguilera, S. Gaur and Z. Nahleh, Adherence to adjuvant aromatase inhibitor therapy among postmenopausal hispanic/latino women with breast cancer, Anticancer Res. 40(2) (2020) 857–864; https://doi.org/10.21873/anticanres.14018 Search in Google Scholar

54 E. Ekinci, S. Nathoo, T. Korattyil, A. Vadhariya, H. A. Zaghloul, P. A. Niravath, S. M. Abughosh and M. V. Trivedi, Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence?, J. Cancer Survivorship 12(3) (2018) 348–356; https://doi.org/10.1007/s11764-017-0674-4 Search in Google Scholar

55 V. Ziller, I. Kyvernitakis, D. Knöll, A. Storch, O. Hars and P. Hadji, Influence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment - the COMPAS study, BMC Cancer 13 (2013) Article ID 407 (9 pages); https://doi.org/10.1186/1471-2407-13-407 Search in Google Scholar

56 C. Markopoulos, P. Neven, M. Tanner, M. Marty, R. Kreienberg, L. Atkins, A. Franquet, M. Gnant, S. Neciosup, P. Tesarova, S. Barni and V. Deschamp, Does patient education work in breast cancer? Final results from the global CARIATIDE study, Future Oncol. 11(2) (2015) 205–217; https://doi.org/10.2217/fon.14.179 Search in Google Scholar

57 V. L. Wagner, W. Jing, F. P. Boscoe, M. J. Schymura, P. J. Roohan and F. C. Gesten, Improving adjuvant hormone therapy use in medicaid managed care-insured women, New York State, 2012–2014, Prev. Chronic Dis. 13 (2016) 1–9; https://doi.org/10.5888/pcd13.160185 Search in Google Scholar

58 K. D. Yu, Y. Zhou, G. Y. Liu, B. Li, P. Q. He, H. W. Zhang, L. H. Lou, X. J. Wang, S. Wang, J. H. Tang, Y. H. Liu, X. Wang, Z. F. Jiang, L. W. Ma, L. Gu, M. Z. Cao, Q. Y. Zhang, S. M. Wang, F. X. Su, H. Zheng, H. Y. Li, L. L. Tang, S. R. Sun, J. P. Liu, Z. M. Shao and Z. Z. Shen, A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients’ persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer, Breast Cancer Res. Treat. 134(1) (2012) 307–313; https://doi.org/10.1007/s10549-012-2059-8 Search in Google Scholar

59 P. Hadji, M. Blettner, N. Harbeck, C. Jackisch, H. J. Lück, C. Windemuth-Kieselbach, S. Zaun and R. Kreienberg, The patient’s anastrozole compliance to therapy (PACT) program: A randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cance, Ann. Oncol. 24(6) (2013) 1505–1512; https://doi.org/10.1093/annonc/mds653 Search in Google Scholar

60 A. S. Oberguggenberger, M. Sztankay, B. Beer, B. Schubert, V. Meraner, H. Oberacher, G. Kemmler, J. Giesinger, E. Gamper, B. Sperner-Unterweger, C. Marth, B. Holzner and M. Hubalek, Adherence evaluation of endocrine treatment in breast cancer: Methodological aspects, BMC Cancer 12 (2012) Article ID 474 (9 pages); https://doi.org/10.1186/1471-2407-12-474 Search in Google Scholar

61 M. J. Stirratt, J. Dunbar-Jacob, H. M. Crane, J. M. Simoni, S. Czajkowski, M. E. Hilliard, J. E. Aikens, C. M. Hunter, D. I. Velligan, K. Huntley, G. Ogedegbe, C. S. Rand, E. Schron and W. J. Nilsen, Self-report measures of medication adherence behavior: recommendations on optimal use, Transl. Behav. Med. 5(4) (2015) 470–482; https://doi.org/10.1007/s13142-015-0315-2 Search in Google Scholar